Linkedin
Facebook
Twitter
Youtube

22 Jul Emendo Biotherapeutics

Posted at 21:10h in by

Rachel Diamant, Chief Intellectual Property Officer and Head of Pipeline Development

Oct. 12 | 10:45am | BlueRock Therapeutics Ballroom

Miami, FL
(Private)

In-person Presentation
EmendoBio is a pioneering, next-generation CRISPR company. Our unique approach allows us to make any gene targetable, transforming the current landscape of genetic medicine. Founded and managed by a core group of graduates from the Weizmann Institute of Science, EmendoBio’s scientific team combines expertise in protein engineering, molecular biology, and gene editing systems. Our dual OMNI™ technology platforms enable us to perform precision gene editing while maintaining high efficiencies, allowing us to address disorders and diseases that were previously considered incurable.
www.emendobio.com



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,200 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 12-14, 2021
Carlsbad, CA

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions